Asset Comparison and Correlation

Given investment horizon of 30 days, Nektar Therapeutics is expected to under-perform the Generex. But the stock apears to be less risky and, when comparing its historical volatility, Nektar Therapeutics is 1.64 times less risky than Generex. The stock trades about -0.17 of its potential returns per unit of risk. The Generex Biotechnology Corporation is currently generating about -0.07 of returns per unit of risk over similar time horizon. If you would invest 10.00 in Generex Biotechnology Corporation on April 26, 2012 and sell it today you would earn a total of 0.00 from holding Generex Biotechnology Corporation or generate 0.0% return on investment over 30 days.